OR WAIT null SECS
March 08, 2021
USP is collaborating with Phlow to build a new lab that will develop test methods and standards to facilitate broader adoption of continuous manufacturing.
March 02, 2021
FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
February 16, 2021
The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.
February 03, 2021
Advanced manufacturing technologies are available, but challenges need to be addressed.
December 03, 2020
Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.
November 18, 2020
The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
November 03, 2020
Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.
September 21, 2020
Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.
September 03, 2020
Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections.